期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
我国心血管病治疗中药“丹参多酚酸盐”研制成功
1
《世界科学技术-中医药现代化》 2005年第4期115-115,共1页
在科技部“十五”国家重大科技专项“创新药物和中药现代化”的支持下,中国科学院上海药物研究所历时13年研制成功开发了具有较高科技含量的心血管病治疗药“丹参多酚酸盐、注射用丹参多酚酸盐”,丹参多酚酸盐的相关技术相继获得中国... 在科技部“十五”国家重大科技专项“创新药物和中药现代化”的支持下,中国科学院上海药物研究所历时13年研制成功开发了具有较高科技含量的心血管病治疗药“丹参多酚酸盐、注射用丹参多酚酸盐”,丹参多酚酸盐的相关技术相继获得中国和美国专利的授权。2005年5月25日国家食品药品监督管理局正式批准颁发了新药和生产批文。 展开更多
关键词 心血管病治疗 丹参多酚酸盐 现代化 研制成功 国家食品品监督管理局 上海物研究所 中国科学院 创新 科技含量
在线阅读 下载PDF
八十年代以来心血管疾病药物治疗学的进展 被引量:5
2
作者 方圻 《中国循环杂志》 CSCD 1990年第4期342-347,共6页
在跨入九十年代之际,回顾一下八十年代以来心血管病药物治疗学的进展,可以看到在许多方面都有显著的成绩。回顾过去,展望未来,可以帮助我们掌握现状,寻找差距和存在的问题,便于我们制订努力的方向。一、心力衰竭的治疗几十年来,心力衰... 在跨入九十年代之际,回顾一下八十年代以来心血管病药物治疗学的进展,可以看到在许多方面都有显著的成绩。回顾过去,展望未来,可以帮助我们掌握现状,寻找差距和存在的问题,便于我们制订努力的方向。一、心力衰竭的治疗几十年来,心力衰竭的经典疗法是强心甙和利尿剂,八十年代的进展是非糖甙类强心药物的应用。 展开更多
关键词 心血管病药
在线阅读 下载PDF
THBS4 in Disease:Mechanisms,Biomarkers,and Therapeutic Opportunities
3
作者 HUANG De-Ying LI Yan-Hong +1 位作者 BAI Xiu-Feng LIU Yi 《生物化学与生物物理进展》 2025年第9期2217-2232,共16页
Thrombospondin 4(THBS4;TSP4),a crucial component of the extracellular matrix(ECM),serves as an important regulator of tissue homeostasis and various pathophysiological processes.As a member of the evolutionarily conse... Thrombospondin 4(THBS4;TSP4),a crucial component of the extracellular matrix(ECM),serves as an important regulator of tissue homeostasis and various pathophysiological processes.As a member of the evolutionarily conserved thrombospondin family,THBS4 is a multidomain adhesive glycoprotein characterized by six distinct structural domains that mediate its diverse biological functions.Through dynamic interactions with various ECM components,THBS4 plays pivotal roles in cell adhesion,proliferation,inflammation regulation,and tissue remodeling,establishing it as a key modulator of microenvironmental organization.The transcription and translation of THBS4 gene,as well as the activity of the THBS4 protein,are tightly regulated by multiple signaling pathways and extracellular cues.Positive regulators of THBS4 include transforming growth factorβ(TGF-β),interferonγ(IFNγ),granulocyte-macrophage colony-stimulating factor(GM-CSF),bone morphogenetic proteins(BMP12/13),and other regulatory factors(such as B4GALNT1,ITGA2/ITGB1,PDGFRβ,etc.),which upregulate THBS4 at the mRNA and/or protein level.Conversely,oxidized low-density lipoprotein(OXLDL)acts as a potent negative regulator of THBS4.This intricate regulatory network ensures precise spatial and temporal control of THBS4 expression in response to diverse physiological and pathological stimuli.Functionally,THBS4 acts as a critical signaling hub,influencing multiple downstream pathways essential for cellular behavior and tissue homeostasis.The best-characterized pathways include:(1)the PI3K/AKT/mTOR axis,which THBS4 modulates through both direct and indirect interactions with integrins and growth factor receptors;(2)Wnt/β-catenin signaling,where THBS4 functions as either an activator or inhibitor depending on the cellular context;(3)the suppression of DBET/TRIM69,contributing to its diverse regulatory roles.These signaling connections position THBS4 as a master regulator of cellular responses to microenvironmental changes.Substantial evidence links aberrant THBS4 expression to a range of pathological conditions,including neoplastic diseases,cardiovascular disorders,fibrotic conditions,neurodegenerative diseases,musculoskeletal disorders,and atopic dermatitis.In cancer biology,THBS4 exhibits context-dependent roles,functioning either as a tumor suppressor or promoter depending on the tumor type and microenvironment.In the cardiovascular system,THBS4 contributes to both adaptive remodeling and maladaptive fibrotic responses.Its involvement in fibrotic diseases arises from its ability to regulate ECM deposition and turnover.The diagnostic and therapeutic potential of THBS4 is particularly promising in oncology and cardiovascular medicine.As a biomarker,THBS4 expression patterns correlate significantly with disease progression and patient outcomes.Therapeutically,targeting THBS4-mediated pathways offers novel opportunities for precision medicine approaches,including anti-fibrotic therapies,modulation of the tumor microenvironment,and enhancement of tissue repair.This comprehensive review systematically explores three key aspects of THBS4 research:(1)the fundamental biological functions of THBS4 in ECM organization;(2)its mechanistic involvement in various disease pathologies;(3)its emerging potential as both a diagnostic biomarker and therapeutic target.By integrating recent insights from molecular studies,animal models,and clinical investigations,this review provides a framework for understanding the multifaceted roles of THBS4 in health and disease.The synthesis of current knowledge highlights critical research gaps and future directions for exploring THBS4-targeted interventions across multiple disease contexts.Given its unique position at the intersection of ECM biology and cellular signaling,THBS4 represents a promising frontier for the development of novel diagnostic tools and therapeutic strategies in precision medicine. 展开更多
关键词 thrombospondin 4 cancers cardiovascular diseases fibrotic diseases targeted pharmacological
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部